Filing Flows

Filing Flows › Companies › Xeris Biopharma Holdings › Cash flow

Xeris Biopharma Holdings cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$35.5M in Q3 2026 · $73.6M over twelve months

Operating cash flow$35.5M
Free cash flow+$35.5M
Cash / net income3.1×
Cash conversion cycle574 days

Analysis

In Q3 2026, Xeris Biopharma Holdings generated $35.5M of operating cash flow. That is $17.0M more than in Q3 2025 ($18.4M).

Over the twelve months to Sep 30, 2026, operating cash flow was $73.6M; the largest uses were taxes on employees’ shares ($19.5M), other financing ($16.2M), other investing ($1.0M); besides operations, cash came from shares issued ($2.6M); the cash balance rose by $39.5M.

Operating cash flow was $35.5M against net income of $11.3M — 3.1× profit, cash ran ahead of reported earnings. The largest differences: stock-based pay +$10.8M, receivables −$10.5M, accrued liabilities +$7.4M.

Its cash conversion cycle was 574 days (receivables 54 + inventory 584 − payables 64).

Free cash flow

Xeris Biopharma Holdings: free cash flow by quarterXeris Biopharma Holdings: free cash flow by quarter$2.0MQ4 2024−$10.0MQ1 2025$182KQ2 2025$18.4MQ3 2025$20.0MQ4 2025$9.9MQ1 2026$8.3MQ2 2026$35.5MQ3 2026
Operating cash flow less capital spending.
Xeris Biopharma Holdings: operating cash flow against capital spendingXeris Biopharma Holdings: operating cash flow against capital spendingOperating cash flowCapital spending$2.0M$0Q4 2024−$10.0M$0Q1 2025$182K$0Q2 2025$18.4M$0Q3 2025$20.0M$0Q4 2025$9.9M$0Q1 2026$8.3M$0Q2 2026$35.5M$0Q3 2026
Latest (Q3 2026): Operating cash flow $35.5M, Capital spending $0.

Capital allocation, year by year

Xeris Biopharma Holdings: where the cash came from (up) and went (down), by fiscal yearXeris Biopharma Holdings: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$95.5MFY2021: Shares issued $27.2MFY2021: Capital spending −$1.1M$27.2MFY2021FY2022: Operating cash flow −$103MFY2022: Net borrowing $103MFY2022: Shares issued $30.0M$133MFY2022FY2023: Operating cash flow −$47.0MFY2023: Shares issued $32K$32KFY2023FY2024: Operating cash flow −$37.0MFY2024: Shares issued $489K$489KFY2024FY2025: Operating cash flow $28.6MFY2025: Shares issued $11.6M$40.2MFY2025
Over these 5 years operating cash flow totalled −$254M; the largest uses were operating cash flow ($282M) and capital spending ($1.1M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$131M
Debt$190M
Net debt$58.6M
Due within a year$63.8M

Xeris Biopharma Holdings funds itself: free cash flow was $73.6M over the last twelve months, and $131M of cash and investments stands against $190M of debt ($63.8M due within a year, 2.1× covered by cash).

Xeris Biopharma Holdings: debt maturities by year (FY2025)Xeris Biopharma Holdings: debt maturities by year (FY2025)$33.6MYear 3$200MYear 4
Principal due in each year as disclosed in the annual report, against $131M of cash and investments now.

Where the cash came from and went

Xeris Biopharma Holdings: sources (+) and uses (−) of cash, Q3 2026Xeris Biopharma Holdings: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$35.5MOther financing−$25.9MCash drawn (+) / kept (−)−$9.3MTaxes on employees’ shares−$752KShares issued$628KOther investing−$159K
Xeris Biopharma Holdings: sources (+) and uses (−) of cash, TTM to Q3 2026Xeris Biopharma Holdings: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$73.6MCash drawn (+) / kept (−)−$39.5MTaxes on employees’ shares−$19.5MOther financing−$16.2MShares issued$2.6MOther investing−$1.0M

From profit to cash

Xeris Biopharma Holdings: net income to operating cash flow, Q3 2026Xeris Biopharma Holdings: net income to operating cash flow, Q3 2026Net income$11.3MDepreciation & amortization$300KStock-based pay$10.8MReceivables−$10.5MInventory$2.7MPayables−$1.2MAccrued liabilities$7.4MPrepaid and other assets$1.3MOther liabilities$1.5MOperating cash flow$35.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20265458464574
Q2 20265756476545
Q1 20265860862604
Q4 20255657240588
Q3 20256656467563
Q2 20256345960462
Q1 20256552045540
Q4 20246245347468

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$35.5M$628K−$9.3M$35.5M
Q2 2026$8.3M$549K−$10.0M$8.3M
Q1 2026$9.9M$847K−$708K$9.9M
Q4 2025$20.0M$584K−$19.4M$20.0M
Q3 2025$18.4M$5.2M−$32.2M$18.4M
Q2 2025$182K$972K−$845K$182K
Q1 2025−$10.0M$4.9M$13.2M−$10.0M
Q4 2024$2.0M$30K−$12.4M$2.0M

Xeris Biopharma Holdings: income statement and cash flow

Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%. The chart follows the revenue to costs, profit and cash.

Xeris Biopharma Holdings: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.